Clinical trial
Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment
NCT00134953 · Novartis, Industry · Terminated
Key facts
| NCT number | NCT00134953 |
|---|---|
| Title | Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment |
| Official title | Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment |
| Lead sponsor | Novartis, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cognitive Symptoms |
| Intervention type | Drug |
| Interventions | Rivastigmine |
| Enrollment | 24 |
| Start date | Jan 1, 2003 |
| Completion | May 1, 2004 |
| First posted | Aug 25, 2005 |
| Last update posted | Dec 17, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: